ATE549017T1 - Verwendung von tranilast und seinen derivaten zur behandlung von neurologischen zuständen - Google Patents
Verwendung von tranilast und seinen derivaten zur behandlung von neurologischen zuständenInfo
- Publication number
- ATE549017T1 ATE549017T1 AT08787273T AT08787273T ATE549017T1 AT E549017 T1 ATE549017 T1 AT E549017T1 AT 08787273 T AT08787273 T AT 08787273T AT 08787273 T AT08787273 T AT 08787273T AT E549017 T1 ATE549017 T1 AT E549017T1
- Authority
- AT
- Austria
- Prior art keywords
- tranilast
- derivatives
- neurological conditions
- treatment
- neuronal
- Prior art date
Links
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 title abstract 3
- 229960005342 tranilast Drugs 0.000 title abstract 3
- 230000000926 neurological effect Effects 0.000 title abstract 2
- 230000001537 neural effect Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 230000035771 neuroregeneration Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 238000009168 stem cell therapy Methods 0.000 abstract 1
- 238000009580 stem-cell therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07016189A EP2030617A1 (de) | 2007-08-17 | 2007-08-17 | Verwendungen von Tranilast und Derivaten daraus zur Behandlung neurologischer Leiden |
| PCT/EP2008/060745 WO2009024543A1 (en) | 2007-08-17 | 2008-08-15 | Use of tranilast and derivatives thereof for the therapy of neurological conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE549017T1 true ATE549017T1 (de) | 2012-03-15 |
Family
ID=38645596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08787273T ATE549017T1 (de) | 2007-08-17 | 2008-08-15 | Verwendung von tranilast und seinen derivaten zur behandlung von neurologischen zuständen |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110112187A1 (de) |
| EP (2) | EP2030617A1 (de) |
| AT (1) | ATE549017T1 (de) |
| AU (1) | AU2008290583A1 (de) |
| CA (1) | CA2696582A1 (de) |
| WO (1) | WO2009024543A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ574028A (en) | 2006-07-05 | 2010-10-29 | Fibrotech Therapeutics Pty Ltd | Tranilast analogues (substituted cinnamoyl anthranilate compounds) for treatment of conditions associated with firbrosis |
| SG10201506526QA (en) | 2007-12-21 | 2015-09-29 | Fibrotech Therapeutics Pty Ltd | Halogenated analogues of anti-fibrotic agents |
| EP2947073B1 (de) | 2009-10-22 | 2019-04-03 | Fibrotech Therapeutics Pty Ltd | Analoga von antifibriotischen mitteln mit kondensierten ringen |
| CN104379130B (zh) | 2012-03-30 | 2018-01-02 | 诺弗米克斯有限公司 | 曲尼司特组合物和共结晶体 |
| US11844774B2 (en) | 2014-04-24 | 2023-12-19 | Omoidesouzou Co., Ltd. | Amyloid fiber formation limiter or inhibitor |
| KR101733085B1 (ko) | 2016-04-20 | 2017-05-08 | 전남대학교산학협력단 | 귀리 추출물 아베난쓰라마이드 c 또는 이의 유도체를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약제학적 조성물 및 건강기능식품 |
| EP3577103A1 (de) | 2017-02-03 | 2019-12-11 | Certa Therapeutics Pty Ltd. | Antifibrotische verbindungen |
| EP3848052A4 (de) | 2018-09-07 | 2022-06-08 | Farnex Incorporated | Äusserliche zubereitung mit nicht-lamellarem flüssigkristall formendem lipid |
| CN117679520A (zh) * | 2022-09-09 | 2024-03-12 | 北京达尔文细胞生物科技有限公司 | 用于防治后遗症期面神经麻痹的药物组合物及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE974350T1 (de) * | 1996-02-07 | 2001-01-25 | Kissei Pharmaceutical Co., Ltd. | Tranilast enthaltendes externum und verfahren zu dessen herstellung |
| WO2004071531A1 (en) * | 2003-02-13 | 2004-08-26 | Licentia Oy | Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia |
| WO2006053390A1 (en) * | 2004-11-17 | 2006-05-26 | Angiogen Pharmaceuticals Pty. Ltd. | A method of modulating b cell functioning |
| ZA200706751B (en) * | 2005-01-14 | 2008-10-29 | Univ Leland Stanford Junior | A method of modulating T cell functioning |
| KR20080016859A (ko) * | 2005-05-16 | 2008-02-22 | 앤지오젠 파마슈티칼스 피티와이. 리미티드 | 통증의 치료를 위한 방법 및 조성물 |
-
2007
- 2007-08-17 EP EP07016189A patent/EP2030617A1/de not_active Withdrawn
-
2008
- 2008-08-15 AU AU2008290583A patent/AU2008290583A1/en not_active Abandoned
- 2008-08-15 CA CA2696582A patent/CA2696582A1/en not_active Abandoned
- 2008-08-15 EP EP08787273A patent/EP2185150B1/de not_active Not-in-force
- 2008-08-15 WO PCT/EP2008/060745 patent/WO2009024543A1/en not_active Ceased
- 2008-08-15 US US12/673,943 patent/US20110112187A1/en not_active Abandoned
- 2008-08-15 AT AT08787273T patent/ATE549017T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| US20110112187A1 (en) | 2011-05-12 |
| WO2009024543A1 (en) | 2009-02-26 |
| CA2696582A1 (en) | 2009-02-26 |
| AU2008290583A1 (en) | 2009-02-26 |
| EP2185150A1 (de) | 2010-05-19 |
| EP2030617A1 (de) | 2009-03-04 |
| EP2185150B1 (de) | 2012-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE551063T1 (de) | Verwendung von bifidobacterium longum zur prophylaxe und behandlung von entzündungen | |
| EA201100441A1 (ru) | Соединения для коррекции уровня мочевой кислоты и способы их применения | |
| UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
| WO2009011871A3 (en) | Thiadiazole modulators of pkb | |
| MY148985A (en) | 2-aminopyridine analogs as glucokinase activators | |
| WO2008046003A3 (en) | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | |
| IL211592A0 (en) | Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries | |
| DE60330181D1 (de) | Actriib-fusionspolypeptide und verwendungen dafür | |
| TW200738657A (en) | Thiazole compounds and methods of use | |
| CR11383A (es) | Derivados piridin-2-il-amino-1,2,4 -tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus | |
| WO2009011880A3 (en) | Heterocyclic modulators of pkb | |
| EA200802118A1 (ru) | Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях | |
| BRPI0810942A2 (pt) | método para tratar, previnir, retardar o início ou o desenvolvimento de uma condição, método para promover a diferenciação ou proliferação de uma célula, método para estimular o crescimento de neuritos ou para intensificar a neurogênese num indivíduo, método para auxiliar no tratamento de um indivíduo, método para diferenciar células-tronco multipotenciais, composição farmacêutica, e kit. | |
| DE602007011908D1 (de) | Verwendung von gpr119-rezeptoragonisten zur vermehrung der knochenmasse und zur behandlung von osteoporose sowie kombinationstherapie dafür | |
| BRPI0815715A8 (pt) | Compostos 5-(-4-(haloalcóxi)fenil)pirimidina-2-amina e composições como inibidores de quinases. | |
| EA201000897A1 (ru) | Соединения и фармацевтические композиции для снижения уровня мочевой кислоты | |
| PA8780101A1 (es) | Imidazopiridazina y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido | |
| ATE438404T1 (de) | Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien | |
| MX2009005725A (es) | Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13. | |
| WO2008156685A3 (en) | Tendon stem cells | |
| MX2012001134A (es) | Composiciones y metodos para inhibicion de la via jak. | |
| WO2008157791A3 (en) | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones | |
| ATE501718T1 (de) | Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen | |
| ATE460936T1 (de) | Pyrazoloä1,5-aüpyrimidine derivate zur verwendung in der behandlung von morbus alzheimer und verwandten leiden | |
| AU2016204146A1 (en) | Methods of Increasing Neuronal Differentiation Using Antibodies to Lysophoshatidic Acid |